Bioproduction Market Overview

The bioproduction market size is projected to grow from US$ 22,337.24 million in 2022 to US$ 63,393.93 million by 2030, and the market is estimated to record a CAGR of 13.9% during 2022–2030. Bioproduction involves the large scale manufacturing of biologics, biosimilars, vaccines, and advanced therapies using living cells, biological systems, and specialized equipment. This market forms the backbone of modern biomanufacturing, supporting innovation in oncology, autoimmune diseases, rare disorders, and emerging cell and gene therapies.

Market Insights and Analyst View

Global biomanufacturing is undergoing a structural transformation as therapy developers move from research scale production to commercial volume manufacturing. The shift is especially visible in cell and gene therapies, where manual and fragmented processes are being replaced by integrated, automated, and closed systems. Automation is becoming a strategic necessity because it improves manufacturing consistency, reduces contamination risk, and lowers cost per batch. Digital solutions that support workflow standardization, data traceability, and GMP compliance are also gaining strong adoption among academic institutions, biotechnology companies, and contract manufacturers. Strategic collaborations between technology providers and therapy developers are accelerating the development of end to end platforms that combine instruments, consumables, reagents, and software.

Sample PDF:- https://www.theinsightpartners.com/sample/TIPRE00020213

Key Growth Drivers Reshaping the Market

One of the strongest growth drivers is the increasing number of biologics and biosimilars entering clinical development and commercialization. Patent expiry of blockbuster biologics is encouraging biosimilar manufacturers to expand capacity and invest in efficient production platforms. At the same time, rising healthcare demand and the need for cost effective therapies are supporting wider adoption of biosimilars across oncology, autoimmune diseases, and metabolic disorders. In parallel, cell and gene therapy pipelines are expanding rapidly, driving demand for advanced manufacturing solutions that support scalability, reproducibility, and regulatory compliance.

Market Segmentation Analysis

The bioproduction market is segmented by product, application, equipment, and end user.
By product, the market includes biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. Biologics and biosimilars accounted for the largest market share in 2022 due to established commercial demand. Cell and gene therapies are expected to register the highest growth rate during the forecast period as more therapies progress toward commercialization.

By application, the market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest market share in 2022, supported by strong biologic pipelines and increasing use of biosimilars to manage treatment costs.

By equipment, the market includes upstream equipment, downstream equipment, bioreactors, and consumables and accessories. Consumables and accessories held the largest share in 2022 and are expected to grow steadily as production volumes increase and single use technologies gain wider acceptance.

By end user, the market is segmented into biopharmaceutical companies, contract manufacturing organizations, and others. Biopharmaceutical companies dominated the market in 2022, while contract manufacturing organizations are projected to grow at the fastest pace due to outsourcing trends and flexible capacity requirements.

Regional Growth Outlook
North America held the largest share of the global bioproduction market in 2022, driven by advanced research infrastructure, high biologics adoption, and strong regulatory frameworks. Asia Pacific is expected to register the highest growth rate during 2022–2030. Growth in this region is supported by increasing investments in biopharmaceutical manufacturing, favorable regulatory initiatives, expanding healthcare infrastructure, and rising demand for advanced therapies. Europe continues to play a significant role due to strong biosimilar development and established biomanufacturing capabilities.

Key Players Driving Market Expansion

• Thermo Fisher Scientific Inc
• Merck KGaA
• F. Hoffmann La Roche Ltd
• Bio Rad Laboratories Inc
• Lonza Group AG
• bbi biotech GmbH
• Danaher Corp
• Sartorius AG

What is the primary factor driving the 13.9% CAGR in the bioproduction market?
The rapid expansion of biologics, biosimilars, and cell and gene therapy pipelines, combined with increasing demand for scalable and automated manufacturing solutions, is the primary driver of market growth.

Which product segment is expected to grow the fastest during 2022–2030?
Cell and gene therapies are expected to register the fastest growth due to rising clinical activity and the transition toward commercial scale manufacturing.

Why are contract manufacturing organizations gaining importance in the bioproduction market?
Contract manufacturing organizations offer flexible capacity, specialized expertise, and cost efficiencies, making them attractive partners for biopharmaceutical companies scaling production and managing complex manufacturing requirements.

Future Outlook

The bioproduction market is expected to remain on a strong growth trajectory through 2030 as biopharmaceutical innovation accelerates and manufacturing scales up globally. Automation, digitalization, and flexible production platforms will become critical competitive differentiators. Companies that invest in scalable technologies, integrated solutions, and strategic partnerships are likely to gain long term advantages as the industry transitions toward high volume, high complexity biomanufacturing.

Related Report:- Swabs Collection Kit Market Opportunities & Trends Analysis 2034